Ebola Hemorrhagic Fever

A highly fatal, acute hemorrhagic fever, clinically very similar to MARBURG VIRUS DISEASE, caused by EBOLAVIRUS, first occurring in the Sudan and adjacent northwestern (what was then) Zaire.

Also Known As:

Networked: 93 relevant articles (11 outcomes, 4 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Vesicular Stomatitis
2.	Infection
3.	Needlestick Injuries (Needlestick Injury)
4.	Ebola Hemorrhagic Fever
5.	Influenza in Birds (Avian Flu)

Experts

1.	Feldmann, Heinz: 4 articles (03/2015 - 01/2003)
2.	Takada, Ayato: 3 articles (05/2013 - 01/2003)
3.	Hensley, Lisa E: 3 articles (11/2011 - 12/2003)
4.	Geisbert, Thomas W: 3 articles (11/2011 - 12/2003)
5.	Bordes, Julien: 2 articles (12/2015 - 06/2015)
6.	de Lamballerie, Xavier: 2 articles (11/2015 - 02/2015)
7.	Mentré, France: 2 articles (11/2015 - 02/2015)
8.	Guedj, Jeremie: 2 articles (11/2015 - 02/2015)
9.	Johnson, Daniel W: 2 articles (10/2015 - 06/2015)
10.	Kalil, Andre C: 2 articles (10/2015 - 06/2015)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Ebola Hemorrhagic Fever:

1.	VaccinesIBA 08/15/2000 - "However, the complete protection achieved with active immunization with VRP, as well as the unique characteristics of the VEE replicon vector, warrant further testing of the safety and efficacy of NP-VRP and GP-VRP in primates as candidate vaccines against Ebola hemorrhagic fever." 06/01/2015 - "Safe and effective vaccines could help to end the ongoing Ebola virus disease epidemic in parts of west Africa, and mitigate future outbreaks of the virus. " 09/01/2014 - "While ebolavirus vaccines have been proposed as an intervention to protect apes, their effectiveness would be improved if we could diagnostically confirm Ebola virus disease (EVD) as the cause of die-offs, establish ebolavirus geographical distribution, identify immunologically naïve populations, and determine whether apes survive virus exposure. " 06/19/2015 - "In the beginning of 2015, the first large-scale trials of two experimental vaccines against Ebola virus disease have begun in West Africa. " 01/04/2016 - "Recent advances in the development of vaccines for Ebola virus disease."
2.	Glycoproteins (Glycoprotein)IBA 01/01/2015 - "These sequences closely resemble those previously observed in the current Ebola virus disease outbreak in West Africa, with glycoprotein and polymerase genes showing the most sequence variation. " 11/15/2007 - "In the present study, we used the mouse model for Ebola hemorrhagic fever to assess the safety and efficacy of a vaccine based on a live attenuated vesicular stomatitis virus expressing the Zaire ebolavirus (ZEBOV) glycoprotein. " 01/01/2015 - "In summary, survivorship was not affected, but the Ebola virus disease course in nonhuman primates is temporally influenced by glycoprotein poly-U editing site populations. " 04/18/2015 - "These findings have contributed to the accelerated development of more potent Ebola virus vaccines that encode the same wild-type glycoprotein antigens as the EBO vaccine, which are being assessed during the 2014 Ebola virus disease outbreak in west Africa. "
3.	Povidone-Iodine (Betadine)FDA LinkGeneric 01/01/2015 - "All products showed excellent virucidal efficacy against EBOV, demonstrating the important role PVP-I can play in helping to prevent and limit the spread of Ebola virus disease. "
4.	LigandsIBA 01/01/2015 - "The promising ligands against ebola virus have been also discussed which will be helpful for researchers to design drugs for the treatment of ebola virus disease. "
5.	Monoclonal AntibodiesIBA 01/01/2012 - "Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever."
6.	AntibodiesIBA 05/01/2013 - "Do therapeutic antibodies hold the key to an effective treatment for Ebola hemorrhagic fever?"
7.	AntigensIBA 08/29/2015 - "ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study." 04/18/2015 - "These findings have contributed to the accelerated development of more potent Ebola virus vaccines that encode the same wild-type glycoprotein antigens as the EBO vaccine, which are being assessed during the 2014 Ebola virus disease outbreak in west Africa. "
8.	6-fluoro-3-hydroxy-2-pyrazinecarboxamideIBA 11/01/2015 - "The polymerase inhibitor favipiravir is a candidate for the treatment of Ebola virus disease. " 02/01/2015 - "Favipiravir: a new medication for the Ebola virus disease pandemic." 02/01/2015 - "Dose regimen of favipiravir for Ebola virus disease." 07/01/2015 - "We used supportive treatment with intravenous fluids, broad-spectrum antibiotics, and experimental treatments with convalescent plasma from two survivors of Ebola virus disease and high-dose favipiravir. "
9.	Antiviral Agents (Antivirals)IBA 11/01/2015 - "Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers." 09/15/2009 - "These findings indicate that RIG-I-based therapies may provide an attractive approach for antivirals against Ebola hemorrhagic fever, and possibly other HF viruses." 01/01/2015 - "Also there is no specific vaccine and treatment for Ebola virus; however, many candidate vaccines and antiviral-drugs such as ZMapp and TKM-Ebola are being developed for Ebola virus disease. "
10.	Ebola VaccinesIBA 09/01/2015 - "The ongoing outbreak of Ebola virus disease in West Africa highlighted the lack of a licensed drug or vaccine to combat the disease and has renewed the urgency to develop a pipeline of Ebola vaccines. " 04/18/2015 - "These findings have contributed to the accelerated development of more potent Ebola virus vaccines that encode the same wild-type glycoprotein antigens as the EBO vaccine, which are being assessed during the 2014 Ebola virus disease outbreak in west Africa. "

Therapies and Procedures

1.	Renal Replacement Therapy (Therapies, Renal Replacement) 04/11/2015 - "The effective treatment of vascular leakage and multiorgan failure by combination of ventilatory support, antibiotic treatment, and renal replacement therapy can sustain a patient with severe Ebola virus disease until virological remission. " 01/01/2015 - "Minimizing risks associated with renal replacement therapy in patients with Ebola virus disease." 01/01/2014 - "Preparing for renal replacement therapy in patients with the Ebola virus disease." 10/01/2015 - "In the severe form, patients with Ebola virus disease may require life-sustaining therapy, including mechanical ventilation and renal replacement therapy. " 10/01/2015 - "The patients received mechanical ventilation, renal replacement therapy, invasive monitoring, vasopressor support, and investigational therapies for Ebola virus disease. "
2.	Therapeutics 01/01/2015 - "The unprecedented 2014-2015 Ebola virus disease (EVD) outbreak in West Africa has highlighted the need for effective therapeutics against filoviruses. " 11/01/2011 - "Therapeutics of Ebola hemorrhagic fever: whole-genome transcriptional analysis of successful disease mitigation." 12/01/2014 - "In light of the current outbreak of Ebola virus disease, there is an urgent need to develop effective therapeutics to treat Ebola infection, and drug repurposing screening is a potentially rapid approach for identifying such therapeutics. " 01/04/2016 - "There are currently no approved therapeutics and preventive vaccines against Ebola virus disease (EVD). " 12/01/2014 - "The number of patients with Ebola Hemorrhagic Fever (EHF) was continuously increasing even though the any effective therapeutics or vaccines has not been developed yet. "
3.	Critical Care 12/01/2015 - "Lessons for pulmonary critical care from treatment of Ebola virus disease in developed countries." 10/01/2015 - "This collective, multicenter experience is presented with the hope that it may inform future treatment of patients with Ebola virus disease requiring critical care treatment." 06/01/2015 - "Ethical and practical considerations in providing critical care to patients with Ebola virus disease." 05/01/2015 - "The care of patients with Ebola virus disease (EVD) requires the application of critical care medicine principles under conditions of stringent infection control precautions. " 10/01/2014 - "Ebola virus disease represents an illness ready for a paradigm shift in care delivery and outcomes, and the profession of critical care medicine can and should be instrumental in helping this happen. "
4.	Investigational Therapies (Experimental Therapy) 07/01/2015 - "The challenges of treating Ebola virus disease with experimental therapies." 04/01/2015 - "Evaluating clinical trial designs for investigational treatments of Ebola virus disease." 10/01/2015 - "The patients received mechanical ventilation, renal replacement therapy, invasive monitoring, vasopressor support, and investigational therapies for Ebola virus disease. " 10/01/2014 - "Daniel Bausch has been assisting with patient care during the current Ebola virus disease outbreak in western Africa and - as part of a WHO-led international collaboration - is exploring the possible use of experimental therapies and vaccines. " 09/10/2014 - "Largest-ever outbreak of Ebola virus disease thrusts experimental therapies, vaccines into spotlight."
5.	Catheters 06/01/2015 - "Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit: response to comments by Bordes et al." 06/01/2015 - "Comments on Rees et al.: Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit." 05/01/2015 - "Early central venous catheter (CVC) insertion in Ebola virus disease (EVD) is a novel approach and has not previously been described. " 05/01/2015 - "Safety and feasibility of a strategy of early central venous catheter insertion in a deployed UK military Ebola virus disease treatment unit."